{"id":"NCT03770403","sponsor":"argenx","briefTitle":"A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.","officialTitle":"A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-03-01","primaryCompletion":"2022-06-23","completion":"2022-06-30","firstPosted":"2018-12-10","resultsPosted":"2023-07-14","lastUpdate":"2023-07-14"},"enrollment":151,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Generalized Myasthenia Gravis"],"interventions":[{"type":"BIOLOGICAL","name":"ARGX-113","otherNames":["efgartigimod"]}],"arms":[{"label":"ARGX-113","type":"EXPERIMENTAL"}],"summary":"This is a Long-Term, Single-Arm, Open-Label, Multicenter Phase 3 follow-on trial of the ARGX-113-1704 study to evaluate the safety and tolerability of ARGX-113 in patients with gMG. Patients who have completed at least 1 cycle of treatment and at least 1 year of trial ARGX-113-1705 and have started Part B are eligible to enroll in the open-label trial ARGX-113-2002 to receive efgartigimod by SC administration.","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious AEs, TEAEs Leading to Study Drug Discontinuation and Fatal TEAE in AChR-Positive Participants","timeFrame":"TEAEs were collected from the start of first administered study treatment (Day 1) up to end of follow-up, approximately up to 3 years","effectByArm":[{"arm":"Efgartigimod","deltaMin":92,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":52,"countries":["United States","Belgium","Canada","Czechia","Denmark","France","Georgia","Germany","Hungary","Italy","Japan","Netherlands","Poland","Russia","Serbia"]},"refs":{"pmids":["38318236","34146511"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":36,"n":145},"commonTop":["Headache","Nasopharyngitis","COVID-19","Diarrhoea","Urinary tract infection"]}}